The historical rank and industry rank for Canopy Growth's OCF Margin % or its related term are showing as below:
FRA:11L'
s OCF Margin % Range Over the Past 10 Years
Min: -236.38 Med: -99.73 Max: -22.42
Current: -22.38
During the past 13 years, the highest OCF Margin % of Canopy Growth was -22.42%. The lowest was -236.38%. And the median was -99.73%.
FRA:11L's OCF Margin % is ranked worse than 87.59% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs FRA:11L: -22.38
Canopy Growth OCF Margin % Related Terms
Canopy Growth OCF Margin % Historical Data
* Premium members only.
The historical data trend for Canopy Growth's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Canopy Growth's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (FRA:11L) has a OCF Margin % of -25.62% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Canopy Growth and its competitors. According to the industry distribution chart, Canopy Growth ranks #840 out of 959 companies in the Drug Manufacturers industry, placing it in the top 87.6%.
Is Canopy Growth's OCF Margin % too high?
Canopy Growth's current OCF Margin % is -25.62%. Based on the distribution chart, Canopy Growth ranks #840 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Canopy Growth has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #840 out of 959 companies for OCF Margin %. This places Canopy Growth in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Canopy Growth and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current OCF Margin % is -25.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (FRA:11L) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €0.83 — trading 27.8% above its estimated fair value. The current OCF Margin % is -25.62%. Canopy Growth's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Canopy Growth (FRA:11L), the current OCF Margin % is -25.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (FRA:11L) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of €0.83 is trading 27.8% above its estimated GF Value™ of €0.65.
GuruFocus considers Canopy Growth to be Modestly Overvalued.
Key valuation signals for FRA:11L:
OCF Margin %: -25.62%
GF Value™: €0.65 vs. price of €0.83 (27.8% above fair value)
No single metric tells the full story. See the FRA:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
59GF Score
Get the complete analysis for FRA:11L
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:11L has been successfully added to your 
